HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, Volume 2, February 2016 Biomedical Research Governance       » Tissue banking in Singapore — An Evolving Enterprise       » China Recognizes Prominent Scientists and Stresses on Innovation       » NUS Researchers Uncover Potent Parasite-killing Mechanism of Nobel Prize-Winning Anti-Malarial Drug       » A New Water Robot "Born" to Detect Water Quality       » Probing the Mystery of How Cancer Cells Die       » Researchers Find Link between Processed Foods and Autoimmune Diseases       » Unravelling the Genetics of Pregnancy and Heart Failure      
INSIDE INDUSTRY
Mundipharma signs exclusive agreement with Helsinn Group for distribution of Anamorelin® across key markets in SEA

Mundipharma has entered a license agreement with Helsinn for the exclusive rights to develop, manufacture and commercialise Anamorelin®, a novel compound for the treatment of weight loss in cancer patients suffering from Non-Small Cell Lung Cancer (NSCLC) across the ten markets of Singapore, Indonesia, Malaysia, the Philippines, Brunei, Myanmar, Cambodia, Laos, Thailand and Vietnam.

Anamorelin® is a synthetic, orally active ghrelin receptor agonist that shows promise to treat cancer anorexia-cachexia in patients suffering from NSCLC. Attributed to about one-third of cancer deaths, cancer anorexia-cachexia syndrome (CACS) is a disorder that is mainly characterized by muscle atrophy and subsequent cancer induced weight loss (CIWL).

Studies have shown that there is a high correlation between CIWL and early deaths for cancer patients, with a significantly higher number of early deaths reported for patients who lost more than 5% of their body weight as compared to those who lost less than 5% of their body weight. It is estimated that over 50% of late-stage cancer patients suffer from cancer anorexia-cachexia and CIWL as a result. With no truly effective treatment available in the market today, products such as Anamorelin® will play a significant role in meeting the needs of this substantial number of patients.

"We are excited to further expand our partnership with Helsinn and supplement our portfolio of products for supportive care of patients with cancer," said Raman Singh, Regional Managing Director of Mundipharma Asia Pacific, Latin America, Middle East and Africa. "This partnership will help us in our mission to alleviate the burden of pain for cancer patients in the key markets where we operate."

Anamorelin® is currently undergoing two phase III studies, ROMANA 1 and ROMANA 2, which are running in parallel, to evaluate the efficacy of the drug in the treatment of CACS. Both of these trials are expected to complete by the end of 1H 2014.

"This partnership is another step in what we foresee as a long and fruitful association with Mundipharma. We are confident that Anamorelin® will present an important advancement in the management of cancer anorexia-cachexia," said Dr Riccardo Braglia, CEO, Helsinn Group.

Click here for the complete issue.

NEWS CRUNCH  
news EmTech Asia Opens: Features 50 speakers on innovation and emerging technologies
news Russia's only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam
news Wheat Genome Sequencing Gets Major Boost
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Primates in Biomedical Research
COLUMNS  
\
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Cancerology / Oncology
May:
Guest Editorial - Antibody Informatics In Japan
June:
Medical Devices and Technology
July:
Water Technology
August:
Occupational Health
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Tobacco Smoking
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy